Read why we think NGL preferred shares are a strong buy with 12%+ yields, improved fundamentals, and low call risk.

As for Seralutinib’s PH-ILD indication, the SERANATA Phase 3 trial will begin site activations in Q4 2025. GOSS has enough ...

The Lenovo Yoga 32i all-in-one desktop stays near the top of its game with a stunning design, wireless charging, and a vivid ...

Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...

According to The Georgetown University Center on Education and the Workforce, an average of 502,000 job openings will be ...

You know that feeling when you spot a car and think, “Wait, that thing’s from when?” That’s Porsche’s specialty: building ...

First, my colleague, Frances Stead Sellers will talk to Amir Dan Rubin, founder and CEO of the VC firm Healthier Capital. He was previously the CEO of One Medical and Stanford Healthcare. We're ...